Contraindicated (one)bortezomib will boost the degree or impact of mavacamten by impacting hepatic enzyme CYP2C19 metabolism. Contraindicated. Sturdy or moderate CYP2C19 inhibitors may well increase mavacamten systemic exposure, resulting in coronary heart failure resulting from systolic dysfunction. Drug Formulary information and facts is intended for use by Health care professionals. https://edenz333rdo6.like-blogs.com/profile